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Abstract
Background: Cancer and its therapies increase the risk of venous thromboembolism. Compared
to patients without cancer, patients with cancer anticoagulated for venous thromboembolism are
more likely to develop recurrent thrombotic events and major bleeding. Addressing all important
outcomes including harm is of great importance to make evidence based health care decisions. The
objective of this study was to compare low molecular weight heparin (LMWH) and oral
anticoagulants (vitamin K antagonist (VKA) and ximelagatran) for the long term treatment of
venous thromboembolism in patients with cancer.
Methods: A systematic review of the medical literature. We followed the Cochrane Collaboration
methodology for conducting systematic reviews. We assessed methodological quality for each
outcome by grading the quality of evidence using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) methodology.
Results: Eight randomized controlled trials (RCTs) were eligible and reported data for patients
with cancer. The quality of evidence was low for death and moderate for recurrent venous
thromboembolism. LMWH, compared to VKA provided no statistically significant survival benefit
(Hazard ratio (HR) = 0.96; 95% CI 0.81 to 1.14) but a statistically significant reduction in venous
thromboembolism (HR = 0.47; 95% (Confidence Interval (CI) = 0.32 to 0.71). There was no
statistically significant difference between LMWH and VKA in bleeding outcomes (RR = 0.91; 95%
CI = 0.64 to 1.31) or thrombocytopenia (RR = 1.02; 95% CI = 0.60 to 1.74).
Conclusion: For the long term treatment of venous thromboembolism in patients with cancer,
LMWH compared to VKA reduces venous thromboembolism but not death.
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Background
The presence of cancer increases the risk of venous throm-
boembolism four to six fold [1]. Cancer related interven-
tions such as chemotherapy, hormonal therapy and
indwelling central venous catheters also increase the risk
of venous thromboembolism [1]. Similarly, patients
undergoing surgery for cancer have a higher risk of venous
thromboembolism than those undergoing surgery for
benign diseases [2,3]. Furthermore, patients with cancer
and venous thromboembolism have a higher risk of death
than patients with cancer alone or with venous throm-
boembolism alone [4,5].
Cancer patients also have different benefits and risks from
anticoagulant treatment than those without cancer. For
instance, during oral anticoagulation therapy for venous
thromboembolism, patients with cancer, compared to
those without cancer, have higher incidence of recurrent
venous thromboembolism (27.1 versus 9.0 events per
100 patient years, p = 0.003) and of major bleeding (13.3
versus 2.2 events per 100 patient years, p = 0.002) [6].
Three systematic reviews have compared low molecular
weight heparin (LMWH) and vitamin K antagonists
(VKA) in the long treatment of venous thromboembo-
lism, but in populations not restricted to patients with
cancer [7-9] The review by van der Heijden et al. did not
complete a preplanned subgroup analysis in patients with
cancer as the required data was not specifically reported
[7] The review by Conti et al. did not conduct a meta-anal-
ysis in the subgroup of patients with cancer [8] In the
review by Ioro et al. a meta-analysis in the subgroup of
patients with cancer found no statistically significant dif-
ference in mortality (OR = 1.13; 95% CI 0.54, 2.38).
No systematic review has focused on the long term treat-
ment of venous thromboembolism in patients with can-
cer. The above mentioned subgroup analysis did not
report on the comparative safety of LMWH and VKA [9]
The Cochrane Collaboration has recognized that address-
ing all important outcomes including harm is of great
importance to make evidence based health care decisions
[10]. In addition, an analysis that includes an evaluation
of direct comparative trials and direct subgroup compari-
son could prevent the potential pitfalls of indirect sub-
group analysis [11].
The objective of this study was to conduct a systematic
review to compare the efficacy and safety of LMWH and
oral anticoagulants for the long term treatment of venous
thromboembolism in patients with cancer.
Methods
Eligibility criteria
We included RCTs including patients with cancer with a
confirmed diagnosis of venous thromboembolism (deep
venous thromboembolism (DVT) or pulmonary embo-
lism). The venous thromboembolic event should have
been diagnosed using an objective diagnostic test. RCTs
should have compared long term treatment with LMWH
versus oral anticoagulants (VKA or ximelagatran) and
should have treated patient groups similarly apart from
the intervention of interest.
Outcomes of interest
Outcomes of interest included: survival, symptomatic
recurrent DVT, symptomatic recurrent pulmonary embo-
lism, major bleeding, minor bleeding, thrombocytopenia,
and postphlebitic syndrome. We accepted the definitions
of major bleeding, minor bleeding, thrombocytopenia
and postphlebitic syndrome of the authors of the original
studies as long as they were standardized.
Data Sources and Searches
The search was part of a comprehensive search for studies
of anticoagulation in patients with cancer. We electroni-
cally searched in January 2007 the following databases
from the date of their inception: The Cochrane Central
Register of Controlled Trials, MEDLINE, EMBASE and ISI
the Web of Science (Additional file 1). We also hand
searched the conference proceedings of the American
Society of Clinical Oncology and of the American Society
of Hematology. We reviewed the reference lists of
included papers and used the related article feature in
PubMed. We applied no language restrictions.
Study Selection
Two reviewers independently screened the titles and
abstracts for eligibility. We retrieved the full texts of arti-
cles judged as potentially eligible by at least one reviewer.
Two reviewers then independently screened the full texts
articles for eligibility and resolved their disagreements by
discussion. We included studies published as abstracts
only if authors supplied us with the necessary information
about their methods and results.
Data collection
Two reviewers independently extracted data using a stand-
ardized form and resolved their disagreements by discus-
sion. Extracted data related to participant characteristics,
the details of the interventions, the outcomes and meth-
odological quality indicators. We contacted authors for
incompletely reported data.
We assessed the following methodological criteria for
each study: allocation concealment, blinding (patient,
provider, outcome assessor, data analyst), whether theJournal of Experimental & Clinical Cancer Research 2008, 27:21 http://www.jeccr.com/content/27/1/21
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analysis followed the ITT principle, whether study was
stopped early for benefit, and percentage of follow-up. We
assessed the methodological quality for each outcome by
grading the quality of evidence using the Grading of Rec-
ommendations Assessment, Development and Evalua-
tion (GRADE) approach [12]. The GRADE approach
involves making separate ratings for quality of evidence
for each patient important outcome and identifies five fac-
tors that can lower the quality of the evidence when con-
sidering RCTs: study limitations relating to the above
methodological criteria (lack of allocation concealment;
lack of blinding; failure to adhere to an intention to treat
analysis; stopping early for benefit; and large losses to fol-
low-up), inconsistency of results, indirectness of evidence,
imprecision, and publication bias [13].
We extracted time to event data by abstracting the log(haz-
ard ratio) and its variance from trial reports; if these were
not reported, we digitised the published Kaplan-Meier sur-
vival curves and estimated the log(hazard ratio) and its var-
iance using Parmar's methods [14]. We also noted the
minimum and maximum duration of follow-up, which are
required to make these estimates. We performed these cal-
culations in Stata 9, using a specially written program,
which yielded the reported log(HR) and variance when
used on the data presented in Table V of Parmar 1998 [14].
We also extracted categorical data necessary to conduct
intention-to-treat analyses. We collected outcome event
rates whenever they were reported in each trial. When the
authors did not report and could not provide the number
of events at specific time points, two biostatisticians esti-
mated these numbers independently and in duplicate
from survival curves, if available.
Analysis
We calculated the agreement between the two reviewers
for the assessment of trial eligibility using kappa statistic.
We analyzed, when possible, both time to event data and
binary data. For time to event data, we pooled the
log(HR)s using a random-effects model and the generic
inverse variance facility of RevMan 4.2. For binary data,
for a specific outcome, and for each trial, we used the
intention-to-treat principle to calculate the relative risk.
We then pooled the results of trials with similar compari-
sons using a random-effects model.
We evaluated heterogeneity across trials using the I2 statis-
tics. I2 describes the percentage of total variation across
studies that is due to heterogeneity rather than chance
[15]. The interpretation of I2 depends on the magnitude
and direction of effects as well as the strength of evidence
for heterogeneity (e.g. P value from the chi-squared test,
or a confidence interval for I2) [10]. We used the following
classification based on the value of I2 [15]: 0–30 = low;
30–60 = moderate and worthy of investigation; 60–90 =
severe and worthy of understanding; 90–100 = allowing
aggregation only with major caution.
We created inverted funnel plots of individual study
results plotted against sample size in order to evaluate
possible publication bias. We conducted sensitivity analy-
sis by excluding the study of lowest methodological qual-
ity [16] and then a study that used a different initial
anticoagulant in the two study arms (post hoc analysis)
[17].
Results
Results of the search
Figure 1 shows the trial flow. The search identified 3986
citations, including 322 duplicates. The title and abstract
screening of the 3664 unique citations identified 57 as
potentially eligible for this review. The full text screening
excluded 40 citations for the following reasons: The rea-
sons for excluding the 40 citations are as follows: case
series (1), review (15), retrospective study (4), protocol
(2), observational study (6), trial but not randomized and
controlled (4), no cancer patients included (3), only one
patient with cancer was included (1), and no relevant out-
come (2), comparison of two LMWH (tinzaparin and
dalteparin) (1), 18 months extended treatment with
Ximelagatran versus placebo (1).
Of the remaining 17 eligible RCTs, 11 included patients
with cancer as a subgroup the data of which was not
reported and not obtainable from the authors [18-28]. We
thus report data from eight RCTs, five published in full
text [17,29-33] and one published as an abstract [16]. We
also identified 2 publications related to RCTs we included
in this review [34,35]. Agreement between reviewers for
study eligibility was excellent (kappa = 0.94).
Included studies
Table 1 details the characteristics of the six included stud-
ies. Only one of these studies used a different initial anti-
coagulant in the two study arms (LMWH in the LMWH
group and UFH in the vitamin K antagonist group) [17].
The inverted funnel plot for the outcome of all cause mor-
tality did not suggest publication bias (Figure 2).
Methodological quality of included studies
The concealment of allocation was adequate in three trials
[17,30,32] and unclear in the other 3 [16,29,31]. None of
the studies blinded patients or caregivers, four studies
blinded outcome assessors [17,30-32], and three studies
blinded data analysts [17,30,32]. Five studies (all those
published in full text) conducted ITT analysis [17,29-32];
this was not clear in the study published as an abstract
[16]. Two studies reported a priori sample size calcula-
tions [30,32]. The percentage follow-up ranged from 89%Journal of Experimental & Clinical Cancer Research 2008, 27:21 http://www.jeccr.com/content/27/1/21
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to 100%. None of the studies was stopped early for bene-
fit. The methodological quality varied by outcome. It was
low for mortality, moderate for recurrent VTE, low for
major bleeding and very low for minor bleeding, low for
major bleeding and (Table 2). Table 2 also provides the
absolute reductions in the risks of the different outcomes
for a number of illustrative baseline risks, including low
and high baseline risks.
Effects of interventions
Survival
We used time to event data reported by two studies
[30,32] and supplied by the author of a third study [17].
The pooled analysis showed no statistically significant
survival benefit of LMWH over VKA (HR = 0.96; 95% CI
0.81–1.14; I2 = 0%) (Figure 3).
Three studies reported all cause mortality at three months
[16,17,32]. The pooled analysis showed no statistically
significant difference between LMWH and VKA (RR =
0.78; 95% CI 0.46–1.3; I2 = 17%). In a sensitivity analysis
excluding the study published as an abstract [16], the
results remained non statistically significant (RR = 0.76;
95% CI = 0.37–1.58; I2 = 58%). In a sensitivity analysis
excluding the study that used a different initial anticoagu-
lant in the two study arms [17], the results remained non
Trial flow in the systematic review of long term anticoagulation in patients with cancer and venous thromboembolism Figure 1
Trial flow in the systematic review of long term anticoagulation in patients with cancer and venous throm-
boembolism.
3986 citations identified and screened for 
retrieval 
322 duplicates 
57 potentially eligible citations  
Excluded: (n= 38): case series (1), review 
(15), retrospective study (4), protocol (2), 
observational study (6), trial but not 
randomized and controlled (4), no cancer 
patients included (3), only one patient with 
cancer was included (1), and no relevant 
outcome (2). 
8 RCTs included in the review and in the 
meta-analysis  
19 trials eligible for the review 
11 RCTs not included as cancer subgroups 
data were not available Journal of Experimental & Clinical Cancer Research 2008, 27:21 http://www.jeccr.com/content/27/1/21
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Table 1: Comparative table of randomized controlled trials comparing different types of anticoagulants for the long term 
Study Methods* Interventions† Participants§ Outcomes§ Notes
López-Beret 2001 AC: Not clear Blinded: 
outcome assessors ITT 
analysis Sample size not 
calculated a priori 100% 
follow-up for primary 
outcome
Nadroparin 1.025 AXa 
IU/10 Kg twice daily for 
3 days then randomized 
to Nadroparin 1.025 
antiXa IU/10 Kg twice 
daily versus 
acenocoumarol (target 
INR 2–3) for 3–6 
months. After the 3rd 
month, nadroparin was 
switched to once daily. 
68% of INR values were 
on target.
35 patients with 
known malignancy; 
treated for 
symptomatic DVT of 
the lower limbs; 
minimum age of 18
Death at 12 months Funding: Not 
reported
Meyer 2002 
(CANTHANOX trial)
AC: Adequate Blinded: 
outcome assessors, data 
analysts ITT analysis 
Stopped early for 
insufficient accrual 
Sample size calculated a 
priori 100% follow-up
Enoxaparin 1.5 mg/kg 
daily × 3 months vs. 
Enoxaparin 1.5 mg/kg 
daily × 4 days followed 
by warfarin (target INR 
2–3) × 3 months; 41% of 
time on target.
146 patients with 
cancer (solid or 
hematological; active 
or in remission but on 
treatment); with 
pulmonary embolism 
and/or DVT; minimum 
age of 18 years; 
minimum life 
expectancy of 3 
months
Death, VTE, major 
bleeding at 3 months 
Death, minor 
bleeding, 
thrombocytopenia at 
6 months
Funding: Aventis, 
Assistance 
Publique, 
Hospitaux de 
Paris
Cesarone 2003 Published only as 
abstract AC: Not clear 
Blinding: None, type of   
analysis not clear, Sample 
size calculation: not 
reported 97% follow-up.
Enoxaparin 100 UL/Kg 
twice daily × 3 months 
vs. coumadin (target INR 
3) × 3 months.
199 patients with 
cancer with DVT
Death at 3 months Funding: Not 
reported
Lee 2003 (CLOT trial) AC: Adequate Blinded: 
outcome assessors, data 
analysts ITT analysis 
Sample size calculated a 
priori 99% follow-up
Dalteparin 200 IU/kg 
daily × 1 month followed 
by 150 IU/kg daily × 5 
months vs. Dalteparin 
200 IU/kg daily × 5–7 
days followed by wafarin 
or acecumarol (target 
INR 2–3) × 6 months; 
46% of time on target.
979 patients with 
active cancer and with 
DVT or pulmonary 
embolism or both; 
ECOG 1 or 2
Death, DVT, PE, VTE, 
major bleeding at 6 
months Death at 1 
year
Funding: 
Pharmacia
Dietcher 2006 
(ONCENOX trial)
AC: Not clear Blinding: 
none ITT analysis Sample 
size not calculated a 
priori 89% follow-up
Enoxaparin 1 mg/kg 
twice daily × 5 days 
followed by 1–1.5 mg/kg 
daily × 175 days vs. 
Enoxaparin 1 mg/kg 
twice daily × 5 days 
followed by warfarin 
(target INR 2–3) for a 
total of 180 days
102 active patients 
with cancer with DVT 
and/or PE; minimum 
age of 18 years
Death, recurrent VTE, 
major bleeding, minor 
bleeding at 1 year
Funding: Aventis 
Pharmaceutical
Hull 2006 (LITE study) AC: Adequate Blinded: 
outcome assessors, data 
analysts ITT analysis 
Sample size not 
calculated a priori 99% 
follow-up
Tinzaparin 175 antiXa/kg 
SQ daily for 12 weeks vs. 
UFH for 5 days followed 
by vitamin K antagonist 
(target INR 2–3) for 12 
weeks.
200 patients with 
cancer (solid or 
hematological) with 
proximal DVT with or 
without PE; minimum 
age of 18 years; 
minimum life 
expectancy of 3 
months
Death, recurrent VTE, 
major bleeding, minor 
bleeding, 
thrombocytopenia at 
3 months Death, 
recurrent VTE at 1 
year
Funding: 
Canadian 
Institute for 
Health Research, 
industry grant, 
Leo 
Pharmaceutical, 
Pharmion 
Pharmaceutical 
and Dupont 
Pharmaceutical.
treatment of venous thromboembolism in patients with cancer
* AC = allocation concealment; ITT = intention to treat analysis
† LMWH = Low molecular weight heparin; UFH = Unfractionated heparin
§ DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolismJournal of Experimental & Clinical Cancer Research 2008, 27:21 http://www.jeccr.com/content/27/1/21
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statistically significant (RR = 0.52; 95% CI = 0.26–1.06; I2
= 0%).
Three studies reported all cause mortality at 6 months
[29,30,32]. The pooled analysis showed no statistically
significant difference between LMWH and VKA (RR =
0.94; 95% CI = 0.79–1.11; I2 = 0%).
We finally pooled data from all studies irrespectively of
the timing of outcome assessment and using the 6 months
data from the study by Meyer et al. [32] The pooled anal-
ysis showed no statistically significant difference between
LMWH and VKA (RR = 0.95; 95% CI = 0.81–1.11; I2 = 0%)
(Figure 4). In a sensitivity analysis excluding the study
published as an abstract [16], the results remained non
statistically significant (RR = 0.95; 95% CI = 0.82–1.12; I2
= 0%). In a sensitivity analysis excluding the study that
used a different initial anticoagulant in the two study arms
[17], the results remained non statistically significant (RR
= 0.94; 95% CI = 0.80–1.11; I2 = 0%).
Recurrent venous thromboembolism
We used time to event data reported by two studies
[30,32] and supplied by the author of a third study [17].
The pooled analysis showed a statistically significant ben-
efit of LMWH over VKA (HR = 0.47; 95% CI = 0.32–0.71;
I2 = 0%) (Figure 5). Four studies reported binary data for
venous thromboembolism [17,29,30,32]. The binary data
analysis confirmed the results of the time to event analysis
with a statistically significant benefit of LMWH over VKA
(RR = 0.51; 95% CI = 0.35–0.74; I2 = 0%). In a sensitivity
analysis excluding the study that used a different initial
anticoagulant in the two study arms [17], the results
remained statistically significant (RR = 0.53; 95% CI =
0.35–0.80; I2 = 0%). None of the studies reported DVT
and pulmonary embolism as separate outcomes.
Bleeding outcomes
Four studies assessed bleeding outcomes [17,29,30,32].
The pooled analysis showed no statistically significant dif-
ference between LMWH and VKA for minor bleeding (RR
= 0.85; 95% CI = 0.53–1.35; I2 = 65%), major bleeding
(RR = 1.05; 95% CI = 0.53–2.10; I2 = 42%), and all bleed-
ing (RR = 0.91; 95% CI = 0.64–1.31; I2 = 50%). In a sensi-
tivity analysis excluding the study that used a different
initial anticoagulant in the two study arms [17], the
results remained non statistically significant for all types
of bleeding (minor bleeding: RR = 0.75; 95% CI = 0.41–
1.39; I2 = 73%; major bleeding: RR = 1.09; 95% CI = 0.39–
3.08; I2 = 61%; all bleeding: RR = 0.86; 95% CI = 0.53–
1.38; I2 = 62%).
Thrombocytopenia
Two studies assessed thrombocytopenia as an outcome
[17,32]. The pooled analysis showed no statistically sig-
nificant difference between LMWH and VKA (RR = 1.02;
95% CI = 0.60–1.74; I2 = 0%). In a sensitivity analysis
excluding the study that used a different initial anticoagu-
lant in the two study arms [17], the results remained non
statistically significant (RR = 0.94; 95% CI = 0.52–1.69).
None of the studies reported postphlebitic syndrome as
an outcome.
Discussion
For the long term treatment of venous thromboembolism
in patients with cancer, LMWH compared to VKA pro-
vided no statistically significant survival benefit but a sta-
tistically and patient important reduction in venous
thromboembolism. There was no statistically significant
difference between LMWH and VKA in terms of bleeding
outcomes or thrombocytopenia.
Our systematic approach to searching, study selection and
data extraction should have minimized the likelihood of
missing relevant studies. This increases the confidence in
the internal validity of our findings. A major limitation of
this review is our inability to include in the meta-analyses
11 eligible RCTs with subgroups of patients with cancer
because relevant data was not reported and not obtaina-
ble from the authors. However, the inverted funnel plot
for the outcome of all cause mortality did not suggest pub-
lication bias. This suggests that the treatment effect from
those 11 RCTs should be similar to the one estimated
from the included studies. One has to keep in mind that
funnel plots have limited power to detect bias if the
number of studies is small [10].
Inverted funnel plot for the mortality outcome in rand- omized controlled trials of long term anticoagulation in  patients with cancer and venous thromboembolism Figure 2
Inverted funnel plot for the mortality outcome in 
randomized controlled trials of long term anticoagu-
lation in patients with cancer and venous throm-
boembolism.Journal of Experimental & Clinical Cancer Research 2008, 27:21 http://www.jeccr.com/content/27/1/21
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Table 2: Summary of findings (SoF) table using GRADE methodology
LMWH compared to VKA for patients with cancer requiring long term anticoagulation for VTE
Patient or population: patients with cancer requiring long term anticoagulation for VTE
Settings: Outpatient
Intervention: LMWH
Comparison: VKA
Outcomes Illustrative comparative 
risks* (95% CI)
Relative
effect
  (95% CI)
No of 
Participants
 (studies)
Quality of
the evidence 
 (GRADE)
Comments
Assumed risk Corresponding risk
VKA LMWH
Mortality 
(follow-up: 3–6 months)
Population RR 0.95 
(0.81 to 1.11)
1346 (4) ⊕⊕OO low1,2
310 per 1000 294 per 1000 
(251 to 344)
Low risk population
30 per 1000 28 per 1000 
(24 to 33)
High risk population
1000 per 1000 950 per 1000 
(810 to 1110)
Recurrent VTE 
(binary) 
(follow-up: 3–12 
months)
Population RR 0.51 
(0.35 to 0.74)
1109 (4) ⊕⊕⊕O moderate2
139 per 1000 71 per 1000 
(49 to 103)
Low risk population
40 per 1000 20 per 1000 
(14 to 30)
High risk population
160 per 1000 82 per 1000 
(56 to 118)
Major bleeding 
(follow-up: 3–6 months)
Low risk population RR 1.05 (0.53 to 2.1) 1120 (4) ⊕⊕OO low2,3
30 per 1000 31 per 1000 
(16 to 63)
High risk population
160 per 1000 168 per 1000 
(85 to 336)Journal of Experimental & Clinical Cancer Research 2008, 27:21 http://www.jeccr.com/content/27/1/21
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The pooled results for all cause mortality and bleeding
outcomes showed moderate to severe heterogeneity.
Unfortunately, the number of pooled studies was rela-
tively small to explore the causes of heterogeneity by con-
ducting subgroup analyses. However, the findings suggest
that the trial that used a different initial anticoagulant in
the two study arms is the source of heterogeneity [17].
Three published systematic reviews compared LMWH and
VKA in the long treatment of venous thromboembolism
[7-9]. Two of these systematic reviews showed no statisti-
cally significant reduction of recurrent venous throm-
boembolism by LMWH compared to VKA when the meta-
analysis is not restricted to patients with cancer [7,9].
However, our meta-analysis shows a significant reduction
in recurrent venous thromboembolism in patients with
cancer. The reason for this differential effect in patients
with cancer is not clear. A similar differential effect of anti-
coagulants has been found in the initial treatment of
venous thromboembolism where LMWH was superior to
UFH in patients with cancer but not in patients without
cancer [36].
Of the three published systematic reviews comparing
LMWH and VKA in the long treatment of venous throm-
boembolism [7-9], only the study by Ioro et al. conducted
a meta-analysis in the subgroup of patients with cancer
and found no statistically significant difference in mortal-
ity (OR = 1.13; 95% CI 0.54, 2.38). This finding is consist-
ent with the results of our meta-analysis. While the
reduction in venous thromboembolic events with LMWH
in patients with cancer is expected to reduce thrombosis
related mortality, this did not translate into a reduction in
all cause mortality. This finding is not apparently
Minor bleeding 
(follow-up: 3–6 months)
Low risk population RR 0.85 
(0.53 to 1.35)
1120 (4) ⊕OOO very low2,4
120 per 1000 102 per 1000 
(64 to 162)
High risk population
500 per 1000 425 per 1000 
(265 to 675)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 
95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: confidence interval; LMWH: low-molecular-weight heparin; RR: Risk ratio; VKA: vitamin K antagonists; VTE: venous thromboembolism
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the 
estimate.
Very low quality: We are very uncertain about the estimate.
1 RR = 0.95 and 95% CI = 0.81–1.11
2 We could not obtain data for subgroups of patients with cancer in 11 RCTs
3 RR = 1.05; 95% CI = 0.53–2.10
4 Inconsistency was severe (I2 = 65%)
Table 2: Summary of findings (SoF) table using GRADE methodology (Continued)
Comparison of the effects of LMWHs and vitamin K anatomists on survival (time to event analysis) in patients with cancer and  venous thromboembolism Figure 3
Comparison of the effects of LMWHs and vitamin K anatomists on survival (time to event analysis) in patients 
with cancer and venous thromboembolism.Journal of Experimental & Clinical Cancer Research 2008, 27:21 http://www.jeccr.com/content/27/1/21
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explained by an increase in any specific-cause mortality
(e.g. fatal bleeding), but might be due to the lack of power
to detect a reduction in all cause mortality especially that
the results suggest a trend in that direction.
We were not able to conduct subgroup analyses based on
type of cancer because of the lack of data. Such analyses
would be interesting because of the survival benefits of
LMWH in patients with limited small cell lung cancer [37]
and of VKA in patients with small cell lung cancer [38]
that are independent of any antithrombotic effects.
Conclusion
The decision for a patient with cancer and venous throm-
boembolism to start long term LMWH versus oral antico-
agulation should balance the benefits and downsides and
integrate the patient's values and preferences for out-
comes and management options [39]. While LMWH
decreases the incidence of venous thromboembolism and
possibly of death, we speculate that it might be more
costly and less acceptable because of its subcutaneous
route of administration.
Future research should compare LMWH to other anticoag-
ulants such as ximelagatran and fondaparinux. There is
also a need for research assessing patients' values and pref-
erences regarding long term anticoagulant agents for treat-
ing venous thromboembolism. Researchers should
consider making the raw data of RCTs available for indi-
vidual patient data meta-analysis. Further RCTs including
subgroups of patients with cancer should report separate
results for these subgroups.
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